Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: Results from the Australian Scleroderma Cohort Study

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 170-176

  Owen, Claire E ^a   Ngian, Gene Siew ^a   Elford, Kathleen ^a   Moore, Owen A ^b   Stevens, Wendy ^c   Nikpour, Mandana ^c,d   Rabusa, Candice ^c   Proudman, Susanna M ^e,l   Roddy, Janet ^f   Zochling, Jane ^g   Hill, Catherine L ^h,l   Sturgess, Allan ⁱ   Tymms, Kathleen ^j   Youssef, Peter ^k   Sahhar, Joanne ^a,m  

^a SOUTHERN HEALTH   (Australia)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g UNIVERSITY OF TASMANIA   (Australia)

^h QUEEN ELIZABETH HOSPITAL   (Australia)

ⁱ ST GEORGE HOSPITAL   (Australia)

^j CANBERRA HOSPITAL   (Australia)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l UNIVERSITY OF ADELAIDE   (Australia)

^m MONASH UNIVERSITY   (Australia)

more..

Author keywords

Azathioprine; Interstitial lung disease; Mycophenolate mofetil; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; MYCOPHENOLATE MOFETIL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ALOPECIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOPENIA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; RASH; SKIN CANCER; SYSTEMIC SCLEROSIS; AGED; AUSTRALIA; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; FACTUAL DATABASE; LONGITUDINAL STUDY; LUNG; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC; TIME FACTOR; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AUSTRALIA; AZATHIOPRINE; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84994444677     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. STEEN VD, CONTE C, OWENS GR, MEDSGER TA, Jr.: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
2. PLASTIRAS SC, KARADIMITRAKIS SP, ZIAKAS PD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOS HM, TZELEPIS GE: Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
3. REIMER G, STEEN VD, PENNING CA, MEDSGER TA, JR., TAN EM: Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988; 31: 525-32.
4. KHANNA D, TSENG CH, FARMANI N et al.: Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078-85.
5. GOH NS, DESAI SR, VEERARAGHAVAN S et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
6. MOORE OA, GOH N, CORTE T et al.: Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013; 52: 155-60.
7. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
8. HOYLES RK, ELLIS RW, WELLSBURY J et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
9. TASHKIN DP: Insights from the Scleroderma Lung Study California Thoracic Society Symposium-Idiopathic Pulmonary Fibrosis and Pulmonary Complications of Scleroderma. 2013.
10. MAHER TM: Immunosuppression for connective tissue disease-related pulmonary disease. Semin Respir Crit Care Med 2014; 35: 265-73.
11. LIOSSIS SN, BOUNAS A, ANDONOPOULOS AP: Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006; 45: 1005-8.
12. SWIGRIS JJ, OLSON AL, FISCHER A et al.: Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30-6.
13. PLASTIRAS SC, VLACHOYIANNOPOULOS PG, TZELEPIS GE: Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology 2006; 45: 1572.
14. VANTHUYNE M, BLOCKMANS D, WESTHOVENS R et al.: A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-92.
15. GERBINO AJ, GOSS CH, MOLITOR JA: Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133: 455-60.
16. KOUTROUMPAS A, ZIOGAS A, ALEXIOU I, BAROUTA G, SAKKAS LI: Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29: 1167-8.
17. ZAMORA AC, WOLTERS PJ, COLLARD HR, et al.: Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102: 150-5.
18. FISCHER A, BROWN KK, Du BOIS RM et al.: Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheum 2013; 40: 640-6.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
20. LEROY EC, MEDSGER TA, Jr: Criteria for the classification of early systemic sclerosis. J Rheum 2001; 28: 1573-6.
21. SULLIVAN K TD, PINKNEY A, HSU V et al.: Progressive deterioration of patients with scleroderma with pulmonary involvement: 11 year outcomes from the Scleroderma Lung Study (SLS1). [abstract]. Clin Exp Rheumatol 2014; 32 (Suppl. 81): S17-18.
22. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
23. MOORE OA, PROUDMAN SM, GOH N et al.: Quantifying change in pulmonary function as a prognostic marker in systemic sclerosisrelated interstitial lung disease. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S111-6.
24. RIZZI M, SARZI-PUTTINI P, AIROLDI A, ANTIVALLE M, BATTELLINO M, ATZENI F: Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease. Clin Exp Rheumatol 2015; 33 (Suppl. 91): S142-7.
25. SIMEON-AZNAR CP, FONOLLOSA-PLA V, TOLOSA-VILELLA C, SELVA-O'CALLAGHAN A, SOLANS-LAQUE R, VILARDELL-TARRES M: Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30: 1393-8.
26. CLEMENTS PJ, TASHKIN DP, ROTH MD et al.: The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofitil (MMF) are efficacious in treating progressive intestitial lung disease (ILD) in patients with systemic sclerosis (SSc) [abstract]. Arthritis Rheum 2015; 67 (Suppl. 10).
27. MENDOZA FA, NAGLE SJ, LEE JB, JIMENEZ SA: A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheum 2012; 39: 1241-7.
28. VIEGI G, PAOLETTI P, PREDILETTO R et al.: Carbon monoxide diffusing capacity, other indices of lung function, and respiratory symptoms in a general population sample. Am Rev Respir Dis 1990; 141: 1033-9.
29. HOEPER MM, BOGAARD HJ, CONDLIFFE R et al.: Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25 Suppl.): D42-50.20.
30. LEROY EC, MEDSGER TA, Jr: Criteria for the classification of early systemic sclerosis. J Rheum 2001; 28: 1573-6.